IDH2 and B-cell chronic lymphocytic leukemia: Variants with strong therapeutic significance were found in either IDH1, IDH2, or TP53 in three different patients diagnosed with acute myeloid leukemia (AML) or in TP53 in three patients diagnosed with chronic lymphocytic leukemia (CLL).